Can a tablet game sharpen aging minds during breast cancer treatment?

NCT ID NCT04261153

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study explores whether a tablet-based cognitive stimulation program called HAPPYNeuron® is practical for breast cancer patients aged 70 and older. Cancer treatments, especially chemotherapy, can cause memory and thinking problems, and older patients may be at higher risk. The study will have participants complete three 20-minute sessions on a tablet to see if they can and will use the software, aiming to find a way to help reduce cognitive side effects and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HAPPYNeuron® cognitive stimulation software

What this could lead to

If successful, this could point toward a practical, non-drug way to help older breast cancer patients maintain memory and thinking skills during cancer treatment.

What could go wrong

This is a small feasibility study, so it cannot prove the software improves cognition. Older patients may find tablet use difficult, and the program may not be widely adopted.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Henri Becquerel

    Rouen, France